Scope: scope:
Tablets (including antineoplastic drugs), oral liquids, suspensions, sterile bulk drugs (antineoplastic drugs), bulk drugs (including antineoplastic drugs), psychotropic drugs, soft capsules (including antineoplastic drugs), freeze-dried powder injection (including antineoplastic drugs), powder injection (including antineoplastic drugs and cephalosporins), inhalation powder aerosol, oral suspension, oral emulsion and large-capacity injection (including multilayer) bioengineering. Pretreatment and extraction of traditional Chinese medicine; R&D, manufacturing and sales of medical devices; Sales of general chemical products; Self-management and agency for the import and export of various commodities and technologies, except those restricted or prohibited by the state.
The company's main products are: anti-tumor drugs, cardiovascular drugs, surgical drugs, endocrine drugs. The company's annual production capacity will reach 654.38+0.5 billion tablets, 654.38+0 billion injections, 654.38+0 million soft bag infusion bags, 654.38+0 million bottles of oral liquid, 654.38+0 million capsules and 654.38+0 million ointments. All dosage forms of the company have passed the national GMP certification, and ifosfamide, etoposide, mesna and Tetep have passed the US FDA certification. At the same time, the company is carrying out FDA certification of the preparation and plans to release the preparation in 2009.
On February 28th, 2020, the List of Drugs for National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2020) published by the National Health Insurance Bureau and Ministry of Human Resources and Social Security showed that Hengrui Pharma's Karezumab entered medical insurance and was officially implemented on March 28th, 20021.
After years of corporate culture construction and development, the company's external corporate image and internal cohesion have been significantly improved. Practice has proved that the construction of enterprise culture is of great significance for promoting enterprise management innovation, promoting the company's future development, enhancing corporate social responsibility and promoting the rapid and healthy development of enterprises:
1. Colorful cultural activities:
Participate in provincial and municipal science and technology competitions and provincial and municipal culture and art festivals;
Organize employee training and travel inspection activities regularly every year;
Regularly hold large-scale single youth networking activities of "love at hand";
On holidays, the company organizes employees to go to other units for entertainment and horizontal communication;
Actively carry out party building work, care for employees, and organize relevant knowledge learning;
Organize football matches, table tennis matches, badminton matches, fun sports meetings and other activities to enrich employees' spare time;
2. Vision and mission
Vision: science and technology-oriented, creating a healthy life for mankind.
Jiangsu hengrui Pharmaceutical Co., Ltd.
Jiangsu hengrui Pharmaceutical Co., Ltd.
Mission: To be a patented pharmaceutical enterprise of China people and strive to build a multinational pharmaceutical group in China.